{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:03:07Z","timestamp":1792544587947,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.1001\/jamadermatol.2021.2905","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T11:14:50Z","timestamp":1629285290000},"page":"1279","source":"Crossref","is-referenced-by-count":172,"title":["Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa"],"prefix":"10.1001","volume":"157","author":[{"given":"Sophie","family":"Glatt","sequence":"first","affiliation":[{"name":"UCB Pharma, Slough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B. E.","family":"Jemec","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital, Roskilde"},{"name":"Health Sciences Faculty, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Forman","sequence":"additional","affiliation":[{"name":"ForCare Clinical Research, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sayed","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Schmieder","sequence":"additional","affiliation":[{"name":"Park Avenue Dermatology, Orange Park, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Weisman","sequence":"additional","affiliation":[{"name":"Medical Dermatology Specialists Inc, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rolleri","sequence":"additional","affiliation":[{"name":"UCB Pharma, Raleigh, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Seegobin","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Baeten","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Ionescu","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[{"name":"Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan","family":"Shaw","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi210042r1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice: hidradenitis suppurativa.","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"doi210042r2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa.","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi210042r3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jdv.v34.1","article-title":"Epidemiology of hidradenitis suppurativa in Germany\u2014an observational cohort study based on a multisource approach.","volume":"34","author":"Kirsten","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi210042r4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1046\/j.1468-3083.2000.00087.x","article-title":"The natural history of hidradenitis suppurativa.","volume":"14","author":"von der Werth","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi210042r5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.det.2010.07.003","article-title":"Hidradenitis suppurativa.","volume":"28","author":"Danby","year":"2010","journal-title":"Dermatol Clin"},{"issue":"9","key":"doi210042r6","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/jdv.v33.9","article-title":"Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.","volume":"33","author":"Chernyshov","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi210042r7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jid.2017.09.008","article-title":"Increased suicide risk in patients with hidradenitis suppurativa.","volume":"138","author":"Thorlacius","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi210042r8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13555-020-00354-2","article-title":"Review of comorbidities of hidradenitis suppurativa: implications for daily clinical practice.","volume":"10","author":"Tzellos","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"doi210042r9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4161\/derm.2.1.12490","article-title":"Comorbidities of hidradenitis suppurativa (acne inversa).","volume":"2","author":"Fimmel","year":"2010","journal-title":"Dermatoendocrinol"},{"issue":"10","key":"doi210042r10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","article-title":"Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa.","volume":"12","author":"Zouboulis","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"doi210042r11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11926-015-0529-9","article-title":"Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis.","volume":"17","author":"Durham","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"doi210042r12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","article-title":"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis.","volume":"19","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"doi210042r13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"doi210042r14","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1093\/emboj\/20.19.5332","article-title":"IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding.","volume":"20","author":"Hymowitz","year":"2001","journal-title":"EMBO J"},{"issue":"5","key":"doi210042r15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1084\/jem.20071978","article-title":"Regulation of inflammatory responses by IL-17F.","volume":"205","author":"Yang","year":"2008","journal-title":"J Exp Med"},{"issue":"10222","key":"doi210042r16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"doi210042r17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis.","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"doi210042r18","article-title":"Bimekizumab versus adalimumab in plaque psoriasis.","author":"Warren","journal-title":"N Engl J Med"},{"issue":"4","key":"doi210042r19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa.","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi210042r20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.v83.5","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"doi210042r21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"9906","key":"doi210042r22","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"doi210042r23","first-page":"1","article-title":"A comparison of international management guidelines for hidradenitis suppurativa.","author":"Hendricks","year":"2019","journal-title":"Dermatology"},{"key":"doi210042r24","author":"Kimball","year":"2016"},{"issue":"10273","key":"doi210042r25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"10273","key":"doi210042r26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab Versus Ustekinumab for the Treatment of Moderate to Severe Plaque Psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"doi210042r27"},{"issue":"6","key":"doi210042r28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.2016.30.issue-6","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.","volume":"30","author":"Kimball","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi210042r29","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.2017.177.issue-5","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi210042r30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents.","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"doi210042r31","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.12688\/f1000research","article-title":"A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa.","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Res"},{"issue":"6","key":"doi210042r32","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction.","volume":"139","author":"Witte-H\u00e4ndel","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi210042r33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2340\/00015555-2794","article-title":"Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab.","volume":"98","author":"Schuch","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"doi210042r34","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial.","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"issue":"1","key":"doi210042r35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000503606","article-title":"Adalimumab dose intensification in recalcitrant hidradenitis suppurativa\/acne inversa.","volume":"236","author":"Zouboulis","year":"2020","journal-title":"Dermatology"},{"issue":"10","key":"doi210042r36","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00403-015-1596-5","article-title":"Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients.","volume":"307","author":"Riis","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"doi210042r37","author":"Martorell","year":"2015"},{"issue":"2","key":"doi210042r38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.2019.33.issue-2","article-title":"Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.","volume":"33","author":"Langley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi210042r39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi210042r40","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jid.2016.11.040","article-title":"Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa.","volume":"137","author":"Egeberg","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi210042r41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/ijd.v59.2","article-title":"Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis.","volume":"59","author":"Phan","year":"2020","journal-title":"Int J Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2782805\/jamadermatology_glatt_2021_oi_210042_1636039123.07222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T11:16:56Z","timestamp":1637147816000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2782805"}},"subtitle":["A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.2905","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}